Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling
Lung · 2026
DOI: 10.1007/s00408-026-00936-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung, 2026. Verfasst von Qi Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medic…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Interleukin-4 Receptor alpha Subunit, Idiopathic Pulmonary Fibrosis, Macrophages. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) of unclear etiology. Dupilumab, a humanized monoclonal antibody binding to interleukin-4 receptor alpha (IL-4Rα), suppresses both IL-4 and IL-13 signaling pathways. However, the therapeutic potential in IPF is unclear. This research aimed to evaluate the antifibrotic efficacy of dupilumab and illustrate the underlying mechanisms.
Methods
The antifibrotic efficacy of dupilumab was assessed both in vitro and in vivo. In vitro, a fibroblast activation model and a macrophage-fibroblast co-culture model were established. In vivo, pulmonary fibrosis was induced in C57BL/6 mice by intratracheal bleomycin injection. Lung function, micro-computed tomography (micro-CT), histopathology, inflammatory responses, and fibrosis-related signaling pathways were assessed.
Results
Dupilumab significantly suppressed TGF-β1-induced fibroblast activation. In the macrophage-fibroblast coculture system, dupilumab inhibited the profibrotic phenotype of IL-4/IL-13-stimulated macrophages, as well as macrophage-induced myofibroblast activation. In bleomycin-challenged mice, dupilumab improved pulmonary function, alleviated radiographic and histopathological fibrosis, reduced inflammatory cell counts and inflammatory cytokine levels in bronchoalveolar lavage fluid. Mechanistically, dupilumab suppressed activation of both the TGF-β1/Smad and JAK/STAT pathways in fibrotic lung tissues.
Conclusions
Dupilumab attenuates pulmonary fibrosis by disrupting profibrotic macrophage-fibroblast crosstalk and suppressing fibroblast activation. In preclinical models, dupilumab mitigated BLM-induced pulmonary inflammation and early-stage fibrosis in mice and inhibited the TGF-β1-Smad and JAK-STAT signal transduction cascades. These findings identify IL-4Rα-mediated signaling as a promising intervention point in pulmonary fibrosis and support further investigation of dupilumab as a candidate therapy for fibrotic lung diseases. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China. ShaoyanGao339@163.com.
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China. honggang.zhou@nankai.edu.cn.
- Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. pumchhh@126.com.
ORCID-Profile: Hui Huang
Zitieren
APA
Chen, Q., Zhang, Y., Wang, S., Chen, R., Shi, Y., Li, Z., Shao, C., Gao, S., Zhou, H., & Huang, H. (2026). Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling. Lung. https://doi.org/10.1007/s00408-026-00936-5
Vancouver
Chen Q, Zhang Y, Wang S, Chen R, Shi Y, Li Z, et al. Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling. Lung. 2026. doi:10.1007/s00408-026-00936-5
BibTeX
@article{Chen2026,
author = {Chen, Qi and Zhang, Yupei and Wang, Shiyang and Chen, Ruxuan and Shi, Yujie and Li, Zhiyi and Shao, Chi and Gao, Shaoyan and Zhou, Honggang and Huang, Hui},
title = {Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling},
journal = {Lung},
year = {2026},
doi = {10.1007/s00408-026-00936-5}
}
EUVIMED